Header Logo

Connection

Melody Cobleigh to Female

Back to Details
This is a "connection" page, showing publications Melody Cobleigh has written about Female.
Melody Cobleigh
Connection Strength
0.728
Female
  1. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374.
    View in: PubMed
    Score: 0.058
  2. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
    View in: PubMed
    Score: 0.053
  3. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
    View in: PubMed
    Score: 0.052
  4. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
    View in: PubMed
    Score: 0.050
  5. HER2-directed treatment of metastatic breast cancer: unanswered questions. Oncology (Williston Park). 2013 Mar; 27(3):176, 178, 180.
    View in: PubMed
    Score: 0.033
  6. Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim.
    View in: PubMed
    Score: 0.032
  7. Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45.
    View in: PubMed
    Score: 0.022
  8. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2.
    View in: PubMed
    Score: 0.021
  9. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31.
    View in: PubMed
    Score: 0.020
  10. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24.
    View in: PubMed
    Score: 0.017
  11. Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
    View in: PubMed
    Score: 0.017
  12. Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors. J Am Coll Radiol. 2023 01; 20(1):71-78.
    View in: PubMed
    Score: 0.016
  13. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.016
  14. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
    View in: PubMed
    Score: 0.015
  15. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. Cancer Rep (Hoboken). 2020 12; 3(6):e1287.
    View in: PubMed
    Score: 0.014
  16. Managing menopausal problems. Cancer Treat Res. 2000; 103:1-23.
    View in: PubMed
    Score: 0.013
  17. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
    View in: PubMed
    Score: 0.013
  18. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
    View in: PubMed
    Score: 0.013
  19. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
    View in: PubMed
    Score: 0.013
  20. Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30.
    View in: PubMed
    Score: 0.013
  21. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497.
    View in: PubMed
    Score: 0.012
  22. Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res. 1998; 94:209-30.
    View in: PubMed
    Score: 0.012
  23. Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
    View in: PubMed
    Score: 0.011
  24. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
    View in: PubMed
    Score: 0.010
  25. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat. 2016 Feb; 156(1):33-43.
    View in: PubMed
    Score: 0.010
  26. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994 Aug 17; 272(7):540-5.
    View in: PubMed
    Score: 0.009
  27. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
    View in: PubMed
    Score: 0.009
  28. Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994; 8 Suppl 3:S59-63.
    View in: PubMed
    Score: 0.009
  29. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21.
    View in: PubMed
    Score: 0.009
  30. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993 Mar; 11(3):474-7.
    View in: PubMed
    Score: 0.008
  31. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
    View in: PubMed
    Score: 0.008
  32. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):997-1002.
    View in: PubMed
    Score: 0.006
  33. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8.
    View in: PubMed
    Score: 0.006
  34. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
    View in: PubMed
    Score: 0.006
  35. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
    View in: PubMed
    Score: 0.006
  36. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
    View in: PubMed
    Score: 0.006
  37. Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. Breast J. 2007 Jan-Feb; 13(1):19-27.
    View in: PubMed
    Score: 0.005
  38. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
    View in: PubMed
    Score: 0.005
  39. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.005
  40. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
    View in: PubMed
    Score: 0.005
  41. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
    View in: PubMed
    Score: 0.005
  42. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004 Nov 16; 31(6):1081-8.
    View in: PubMed
    Score: 0.005
  43. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
    View in: PubMed
    Score: 0.005
  44. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1971-5.
    View in: PubMed
    Score: 0.004
  45. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
    View in: PubMed
    Score: 0.004
  46. Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002 Nov-Dec; 8(6):349-55.
    View in: PubMed
    Score: 0.004
  47. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
    View in: PubMed
    Score: 0.004
  48. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol. 2002 Aug; 13(8):1220-4.
    View in: PubMed
    Score: 0.004
  49. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
    View in: PubMed
    Score: 0.004
  50. Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: a cross-sectional examination. Breast Cancer Res Treat. 2002 Jan; 71(2):113-23.
    View in: PubMed
    Score: 0.004
  51. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
    View in: PubMed
    Score: 0.004
  52. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
    View in: PubMed
    Score: 0.004
  53. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997 Mar; 15(3):974-86.
    View in: PubMed
    Score: 0.003
  54. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995 Nov; 1(1):40-6.
    View in: PubMed
    Score: 0.003
  55. Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):49-53.
    View in: PubMed
    Score: 0.002
  56. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6.
    View in: PubMed
    Score: 0.002
  57. Sequential transplants using mobilized peripheral blood progenitor cells. J Clin Apher. 1994; 9(3):176-82.
    View in: PubMed
    Score: 0.002
  58. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3.
    View in: PubMed
    Score: 0.002
  59. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):223-4.
    View in: PubMed
    Score: 0.002
  60. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8.
    View in: PubMed
    Score: 0.001
  61. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. Cancer Treat Rep. 1983 Sep; 67(9):841-2.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.